Abnormal liver function tests after allogeneic hematopoietic cell transplant (allo-HCT) are common and often multifactorial. The conditioning regimen, GVHD, infections related to immunosuppression and medication side effects account for most of the hepatotoxicity in the post-allograft setting. 1 Hepatotoxicity has been associated with thalidomide derivatives, though it appears to be an infrequently encountered adverse effect. Several cases of biopsy-proven hepatotoxicity attributable to lenalidomide have been reported in both the transplant and non-transplant settings. [2] [3] [4] [5] Lenalidomide has also been shown to increase the activity of GVHD, which may manifest as isolated liver involvement. [6] [7] [8] [9] Pomalidomide was approved in February 2013 for use in treating refractory plasma cell myeloma, and toxicities involving the hepatobiliary system were not frequently seen nor reported in preclinical and clinical studies leading to its FDA approval. 10 We report on a patient who developed a biopsy-proven hepatic necrosis associated with the initiation of pomalidomide after allo-HCT, which resolved on discontinuation of pomalidomide.
A 47-year-old black male was seen in the post-transplant clinic for routine follow-up. He had plasma cell myeloma treated with VDT-PACE for three cycles prior to autologous transplant (auto-HCT). He developed progressive disease early post auto-HCT, and underwent a second auto-HCT 4 months after the first, followed by thalidomide maintenance. He progressed within 10 months after the second auto-HCT, and following bortezomib/dexamethasone salvage therapy achieved a PR. He subsequently underwent a non-myeloablative matched related donor allo-HCT with fludarabine + TBI 200 cGy conditioning. By day 100 post allo-HCT BM evaluation showed residual plasma cell involvement (20.5%) with 98% donor cell engraftment. He was treated with four cycles of carfilzomib, and a repeat BM biopsy 15 months post allo-HCT (in October 2013) showed complete engraftment without evidence of myeloma. He developed NIH severe chronic GVHD, which was managed with immunosuppression and extracorporeal photopheresis.
A PET scan 18 months after allo-HCT was notable for new adenopathy and he had elevated serum markers of his disease, consistent with extramedullary relapse. He was started on pomalidomide at 2 mg daily for 21 days, with dexamethasone 20 mg weekly. He complained of increasing nausea and erythematous palmar rash, consistent with a flare of his chronic GVHD, after 3 weeks of pomalidomide. He was subsequently admitted with profound icterus. His laboratory studies revealed a total bilirubin of 16.2 mg/dL (conjugated bilirubin of 12 mg/dL), AST 552 U/L, ALT 1241 U/L, and alkaline phosphatase of 337 U/L. Prothrombin time was elevated, at 22.8 s. Serologic studies for EBV, CMV, as well as Hepatitis A, B and C viruses were all negative. Laboratory values (and the trend of each during his hospital course and subsequent recovery) are shown in Figure 1 . CT of the abdomen and pelvis was grossly normal. The previously identified adenopathy on the PET scan had significantly improved along with improvement in his serum paraprotein, consistent with a PR.
On biopsy, the liver showed large areas of hepatocyte necrosis, with focal interspersed regions of still-viable hepatocytes (Figure 2) . The necrosis manifested both as individual apoptotic hepatocytes (acidophil bodies) and as swathes of collapsed parenchyma lacking hepatocytes. Hemorrhage and accompanying hemosiderin deposition were present, primarily in zones 2 and 3. The portal tracts contained a chronic inflammatory infiltrate composed of lymphocytes and plasma cells, with occasional eosinophils. The portal tracts demonstrated normal hepatic arteries and portal veins. The bile ducts showed evidence of injury (architectural distortion, mild reactive nuclear atypia), but there was no bile duct inflammation, vacuolation or loss. Cholestasis was not seen.
Given the patient's history of allo-HCT, GVHD was considered as a plausible cause for the hepatic necrosis. Typical pathologic features of acute and chronic liver GVHD, such as bile duct loss and inflammation of the endothelium, were absent. As there was slight evidence of bile duct injury, mild background GVHD could not be entirely ruled out but was not considered to be the primary cause of his liver injury. As pomalidomide has been linked to venous thromboembolism, vascular ischemia was also included in the initial differential diagnosis. However, coagulative necrosis predominantly involving zone 3 was not seen, and the hepatic arteries, portal veins and central veins were all viable and patent, with no evidence of obliteration or thromboembolic phenomena. Thus, this diagnosis was similarly not favored.
Though microscopic features of hepatic injury secondary to pomalidomide have not been described, the findings were considered most in keeping with massive hepatic necrosis due to drug-induced liver injury, implicating pomalidomide, and this was discontinued. He was seen in the outpatient setting 2 weeks later, at which point the markers of hepatic injury had nearly normalized (Figure 1 ). This case calls to attention an important toxicity that appears to be attributable to pomalidomide, a toxicity that has not been previously described for this drug but warrants further investigation and consideration when used in the postallograft setting. The bile ducts displayed reactive changes but were not inflamed or destroyed, and the hepatic arteries, portal veins and central veins were viable and patent, without evidence of endothelialitis. These findings argued against GVHD or vascular ischemia as the primary etiology of the liver injury (hematoxylin and eosin stain).
